Please login to the form below

Not currently logged in
Email:
Password:

Bioniche appoints James Rae as chair

He previously led several Canadian biopharma firms as CEO

Bioniche has named James Rae, CEO of Viron Therapeutics, as chair of its board of directors.

He replaces Graeme McRae at the Canadian company, with McRae retaining his position as CEO and president.

"Mr Rae brings a wealth of sector experience to our board of directors," said McRae. "His knowledge and network will serve the company well as we work to complete important R&D projects and grow revenues."

Rae has a rich pedigree in the Canadian biopharma industry serving as CEO at several companies.

Prior to joining Viron in 2007, he was CEO of Cytochroma, chair and CEO of Resolution pharma, and chair and CEO of Vaxis Therapeutics.

Extending back even further, he also served as president and CEO of Cangene, where he was responsible for restructuring and orchestrating a takeover of the company.

He began his pharma career at Searle, where he spent 18 years, including several as CEO.

Bioniche also announced several changes to its senior management structure, with Cameron Groome, executive VP, corporate & strategic development; Jim Phillips, senior VP, industry relations; Dr Dragan Rogan, chief veterinary scientific officer and Dr Gary Weber, president, Bioniche Food Safety (US) all leaving the company.

Michael Rubin has joined Bioniche, however, as VP, business development.

1st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics